Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: Opportunities and challenges

AIDS Patient Care and STDs

Volumn 28, Issue 9, 2014, Pages 462-474

  McMahon, James M ^a   Myers, Julie E ^b,c   Kurth, Ann E ^d   Cohen, Stephanie E ^e   Mannheimer, Sharon B ^c   Simmons, Janie ^f   Pouget, Enrique R ^f   Trabold, Nicole ^a   Haberer, Jessica E ^g  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c Division of Infectious Diseases Department of Medicine Columbia University ^*  (United States)

^d NEW YORK UNIVERSITY   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^f NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONCEPTION; CONDOM USE; CONTRACEPTION; DIARRHEA; DRUG COST; DRUG USE; HEADACHE; HEALTH CARE PERSONNEL; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MEN WHO HAVE SEX WITH MEN; NAUSEA; NEPHROTOXICITY; PRE-EXPOSURE PROPHYLAXIS; PRIMARY PREVENTION; PROPHYLAXIS; RISK REDUCTION; UNITED STATES; VIRUS TRANSMISSION; VOMITING;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; FAMILY CHARACTERISTICS; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION; SEXUAL PARTNERS; UNITED STATES;

EID: 84906238458     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0302     Document Type: Article

References (161)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission inBotswana.NEngl JMed 2012;367:423-434.
4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.
5. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States-2014. A Clinical Practice Guideline. U.S. Public Health Service.
6. Mera RM, Rawlings MK, Pechonkina A, Rooney JF, Peschel T, Cheng A. Status of Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) in the United States: An early drug utilization analysis. Paper presented at: 53rd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 10-13, 2013, Denver, CO.
7. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis: Preparing for public use. Curr HIV/AIDS Rep 2010;7: 210-219.
8. Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health 2011;101:982-985.
9. Flash C, Krakower D, Mayer KH. The promise of antiretrovirals for HIV prevention. Curr Infect Dis Rep 2012;14:185-193.
10. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: Lessons learned from trials and treatment studies. Am J Prev Med 2013;44:S91-S98.
11. Stephenson J. Study halted: No benefit seen from antiretroviral pill in preventing HIV in women. JAMA 2011; 305:1952.
12. Marazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN003). Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA, 2013. Abstract 26LB.
13. Corneli A, Perry B, Agot K, et al. FEM-PrEP: Participant explanations for non-adherence. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, 2014. Abstract 959LB.
14. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
15. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008;49:298-308.
16. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013;64:79-86.
17. Hurt CB, Eron JJ, Jr., Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011;53:1265-1270.
18. Center for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. Morb Mortal Wkly Rep 2012;61:586-589.
19. Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2010;55:8-13.
20. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA 2010;107:12381-12386.
21. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008;68:567-578.
22. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: A randomized clinical trial in diverse multinational settings. PLoS Med 2012;9:e1001290.
23. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Curr Opin Infect Dis 2012;25:51-57.
24. Donnell D, Baeten JM, Bumpus NN, et al. HIV Protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014;66:340-348.
25. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: A substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013;10:e1001511.
26. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up preexposure prophylaxis for HIV prevention: A systematic review of cost-effectiveness modelling studies. PLoS Med 2013;10:e1001401.
27. Zhao Y, Dimitrov DT, Liu H, Kuang Y. Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions. Bull Math Biol 2013;75:649-675.
28. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PLoS Med 2011; 8:e1001123.
29. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: Combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis 2013;208:224-234.
30. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008;22: 1829-1839.
31. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in theUnited States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-815.
32. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012;156:541-550.
33. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: An epidemic model. J Acquir Immune Defic Syndr 2011;58: e51-e52.
34. World Health Organization, UNICEF. Global HIV/AIDS response: Epidemic update and health sector progress towards universal access: Progress report 2011. http://global-hiv-aids-response-2011-en.pdf. (Last accessed May 18, 2014.)
35. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011. 2013; vol. 23. http://www.cdc .gov/hiv/topics/surveillance/resources/ reports. Published February 2013. (Last accessed May 10, 2014.)
36. Heron M. Deaths: Leading causes for 2009. National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 2012;61:1-94.
37. Higgins JA, Hoffman S, Dworkin SL. Rethinking gender, heterosexual men, and womens vulnerability to HIV/AIDS. Am J Public Health 2010;100:435.
38. Hodder SL, Justman J, Hughes JP, et al. HIV acquisition among women from selected areas of the United States: A cohort study. Ann Intern Med 2013;158:10-18.
39. Opoku-Anane J, Diouf K, Nour NM. New success with microbicides and pre-exposure prophylaxis for human immunodeficiency virus (HIV): Is female-controlled prevention the answer to the HIV epidemic? Rev Obstetr Gynecol 2012;5:50.
40. Carpenter CC, Mayer KH, Stein MD, Leibman BD, Fisher A, Fiore TC. Human immunodeficiency virus infection in North American women: Experience with 200 cases and a review of the literature. Medicine 1991;70:307-325.
41. Evans B, Kell P, Bond R, MacRae K. Heterosexual relationships and condom-use in the spread of sexually transmitted diseases to women. Genitourin Med 1995;71: 291-294.
42. De Zoysa I, Sweat MD, Denison JA. Faithful but fearful: Reducing HIV transmission in stable relationships. AIDS 1996;10:S197-S204.
43. Misovich SJ, Fisher JD, Fisher WA. Close relationships and elevated HIV risk behavior: Evidence and possible underlying psychological processes. Rev Gen Psychol 1997;1:72.
44. Finer LB, Darroch JE, Singh S. Sexual partnership patterns as a behavioral risk factor for sexually transmitted diseases. Family Planning Perspect 1999;31:228-236.
45. Pulerwitz J, Izazola-Licea J-A, Gortmaker SL. Extrarelational sex among Mexican men and their partners risk of HIV and other sexually transmitted diseases. Am J Public Health 2001;91:1650-1652.
46. McMahon JM, Tortu S. Evaluation of HIV intervention scenarios targeted to drug-using women from East Harlem: A mathematical modeling approach. Strategies to Improve the Replicability, Sustainability, and Durability of HIV Prevention Interventions for Drug Users. Washington: US Department of Health and Human Services, 2003.
47. McMahon J, Tortu S, Pouget E, Hamid R, Torres L. Increased sexual risk behavior and high HIV seroincidence among drug-using low-income women with primary heterosexual partners. Paper presented at: Int Conf AIDS, Bangkok, Thailand, 2004.
48. El-Bassel N, Witte SS, Gilbert L, et al. HIV prevention for intimate couples: A relationship-based model. Families Syst Health 2001;19:379.
49. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: An analysis of survey and clinical data. Lancet 2008;371:2183-2191.
50. Kalichman SC, Rompa D, Luke W, Austin J. HIV transmission risk behaviours among HIV-positive persons in serodiscordant relationships. Intl J STD AIDS 2002;13:677-682.
51. Wilson SR, Lavori PW, Brown NL, Kao Y-M. Correlates of sexual risk for HIV infection in female members of heterosexual California Latino couples: An application of a Bernoulli process model. AIDS Behav 2003;7:273-290.
52. van der Straten A, Gomez CA, Saul J, Quan J, Padian N. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS 2000;14:F47-F54.
53. Buchacz K, van der Straten A, Saul J, Shiboski SC, Gomez CA, Padian N. Sociodemographic, behavioral, and clinical correlates of inconsistent condom use in HIVserodiscordant heterosexual couples. J Acquir Immune Defic Syndr 2001;28:289-297.
54. El-Bassel N, Jemmott JB, Landis JR, et al. National Institute of Mental Health Multisite Eban HIV/STD Prevention Intervention for African American HIV Serodiscordant Couples: A cluster randomized trial. Arch Intern Med 2010;170:1594-1601.
55. Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples: The potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488 e481-e488.
56. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr 2010;53:619-624.
57. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in Northern California: Results from a ten-year study. Am J Epidemiol 1997;146:350-357.
58. El-Bassel N, Wingood G, Wyatt GE, et al. Concordant and discordant reports on shared sexual behaviors and condom use among African American serodiscordant couples in four cities. AIDS Behav 2010;14:1011-1022.
59. Tortu S, McMahon JM, Hamid R, Neaigus A. Womens drug injection practices in East Harlem: An event analysis in a high-risk community. AIDS Behav 2003;7:317-328.
60. Marks G, Gardner LI, Craw J, et al. The spectrum of engagement in HIV care: Do more than 19% of HIVinfected persons in the US have undetectable viral load? Clin Infect Dis 2011;53:1168-1169.
61. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011;52:793-800.
62. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010;51:725-731.
63. PEPFAR Scientific Advisory Board, El Sadr W, Cohen M, et al. PEPFAR Scientific Advisory Board recommendations for the Office of the US Global AIDS Coordinator: Implications of HPTN 052 for PEPFARs treatment programs; 2011. http://www.pepfar.gov/documents/organization/177126.pdf. (Last accessed November 3, 2013.)
64. World Health Organization. Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: Recommendations for a public health approach, 2012.
65. Mensch BS, van der Straten A, Katzen LL. Acceptability in microbicide and PrEP trials: Current status and a reconceptualization. Curr Opin HIV AIDS 2012;7:534-541.
66. Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Preexposure prophylaxis (PrEP) for HIV infection: Results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS 2013;27:553-559.
67. Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis 2014;58:704-712.
68. Kates J, Levi J. Insurance coverage and access to HIV testing and treatment: Considerations for individuals at risk for infection and for those with undiagnosed infection. Clin Infect Dis 2007;45:S255-S260.
69. Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav 2014;18:195-216.
70. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS One 2012;7: e28238.
71. Mijiti P, Yahepu D, Zhong X, et al. Awareness of and willingness to use oral pre-exposure prophylaxis for HIV prevention among HIV-serodiscordant heterosexual couples: A cross-sectional survey in Xinjiang, China. PLoS One 2013;8:e67392.
72. Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr 2012;61:116-119.
73. Ware NC, Wyatt MA, Haberer JE, et al. Whats love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr 2012;59:463-468.
74. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Edu Prevent 2012;24:408-421.
75. Dunkle K, Wingood G, Camp C, DiClemente R. Intention to use pre-exposure prophylaxis among African-American and white women in the United States: Results from a national telephone survey. Paper presented at: XVII International AIDS Conference, 2008.
76. Auerbach J, Banyan A, Riordan M. Will and should women in the US use PrEP? Findings from a focus group study of at-risk, HIV-negative women in Oakland, Memphis, San Diego and Washington, DC. Paper: International AIDS Society, 2012.
77. Rubtsova A, Wingood G, Dunkle K, Camp C, DiClemente R. Young adult women and correlates of potential adoption of pre-exposure prophylaxis (PrEP): Results of a national survey. Curr HIV Res 2013;11:1-6.
78. Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba AD. Antiviral agents and HIV prevention: Controversies, conflicts, and consensus. AIDS 2012;26:1585-1598.
79. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012;26:F13-F19.
80. Nachega JB, Uthman OA, Mills EJ, Quinn TC. Adherence to antiretroviral therapy for the success of emerging interventions to prevent HIV transmission: A wake up call. J AIDS Clin Res 2012;S4:007.
81. Amico KR, McMahan V, Goicochea P, et al. Supporting study product use and accuracy in self-report in the iPrEx study: Next step counseling and neutral assessment. AIDS Behav 2012;16:1243-1259.
82. Marks G, Crepaz N. HIV-positive mens sexual practices in the context of self-disclosure of HIV status. J Acquir Immune Defic Syndr 2001;27:79-85.
83. Kelly C, Lohan M, Alderdice F, Spence D. Negotiation of risk in sexual relationships and reproductive decisionmaking amongst HIV sero-different couples. Culture Health Sex 2011;13:815-827.
84. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
85. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929.
86. Loutfy MR, Wu W, Letchumanan M, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One 2013;8:e55747.
87. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? J Acquir Immune Defic Syndr 2013; 63:S122-S129.
88. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
89. US Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents: Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents, 2011
90. Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: Considerations of viral load, risk behavior, and health disparities. AIDS Behav 2013; 17:1632-1636.
91. Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention: A narrative review. Ann Intern Med 2012;157:490-497.
92. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: Considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep 2008;5:186-192.
93. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: Current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71.
94. De Man J, Colebunders R, Florence E, Laga M, Kenyon C. What is the place of pre-exposure prophylaxis in HIV prevention? AIDS Rev 2013;15:102-111.
95. Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: A randomized controlled trial. AIDS 2005;19:807-814.
96. Eaton A, van der Straten A. Concurrent sexual partnerships among individuals in HIV sero-discordant heterosexual couples. Int J STD AIDS 2009;20:679-682.
97. Okwundu CI, Okoromah C. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2012;7 Art.No.: CD007189.
98. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One 2012;7:e33103.
99. Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: Antiretroviral pre-exposure prophylaxis. Annu Rev Med 2013;64:219-232.
100. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006;20:2165-2174.
101. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937-946.
102. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51:554-561.
103. Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 2014;28:851-859.
104. Martin M, Vanichseni S, Suntharasamai P, et al. Renal function of participants in the Bangkok Tenofovir Study, Thailand, 2005-2012. Clin Infect Dis 2014; epub May 14.
105. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011;66:240-250.
106. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011;15:S72-S79.
107. Mulligan K, Glidden D, Gonzales P, et al. Effects of emtricitabine/ tenofovir on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 2011.
108. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011;6:e23688.
109. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir- emtricitabine or placebo in Botswana. PloS One 2014;9:e90111.
110. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. (Last accessed June 10, 2014.)
111. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking longterm ART with and without tenofovir in the DART trial. PLoS Med 2012;9:e1001217.
112. Siberry GK, Jacobson DL, Kalkwarf H, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2014. Abstract 71.
113. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 2012;7:e40603.
114. Lehman D, Baeten JM, McCoy C, et al. PrEP exposure and the risk of low-frequency drug resistance. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2014. Abstract 590LB.
115. Pecoraro A, Royer-Malvestuto C, Rosenwasser B, et al. Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States. AIDS Care 2013;25:1399-1406.
116. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007;4:165-172.
117. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: What if it works? Lancet 2007;370: 89-93.
118. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One 2011;6:e18165.
119. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007;2:e875.
120. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2:e27.
121. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Trans Dis 2008;35:1002-1008.
122. Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One 2013;8:e81997.
123. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-422.
124. Kibengo FM, Ruzagira E, Katende D, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: A randomized, clinical trial. PloS One 2013;8.
125. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: A longitudinal analysis. Lancet Infect Dis 2013;13:1021-1028.
126. Underhill K. Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and research ethics. Soc Sci Med 2013;94:115-123.
127. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: Empirical analogies for research and implementation. Curr HIV/AIDS Rep 2010;7:201-209.
128. Lakdawalla D, Sood N, Goldman D. HIV breakthroughs and risky sexual behavior. Quart J Econ 2006;121:1063-1102.
129. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: A meta-analytic review. JAMA 2004;292:224-236.
130. Chen Y. Treatment-related optimistic beliefs and risk of HIV transmission: A review of recent findings (2009- 2012) in an era of treatment as prevention. Curr HIV/AIDS Rep 2013;10:79-88.
131. McDonald K. The old-fashioned way: Conception and sex in serodiscordant relationships after ART. Culture Health Sex 2011;13:1119-1133.
132. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010;54:548.
133. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: A mixed methods study. AIDS Patient Care STDS 2012;26:87-94.
134. Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDS 2011;25:365-370.
135. Mayer KH. Introduction: Linkage, engagement, and retention in HIV care: Essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis 2011;52:S205-S207.
136. Curran K, Baeten JM, Coates TJ, Kurth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep 2012;9:160-170.
137. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;1: Art. No: CD003255.
138. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997;44:1303-1312.
139. Cohen MS. HIV and sexually transmitted diseases: Lethal synergy. Topics HIV Med 2003;12:104-107.
140. Kissinger P, Adamski A. Trichomoniasis and HIV interactions: A review. Sex Trans Infect 2013;89:426-433.
141. Chun HM, Carpenter RJ, Macalino GE, Crum-Cianflone NF. The role of sexually transmitted infections in HIV-1 progression: A comprehensive review of the literature. J Sex Trans Dis 2013;2013:1-15.
142. Chen JL, Phillips KA, Kanouse DE, Collins RL, Miu A. Fertility desires and intentions of HIV-positive men and women. Family Planning Perspect 2001;33:144.
143. Matthews LT, Mukherjee JS. Strategies for harm reduction among HIV-affected couples who want to conceive. AIDS Behav 2009;13:5-11.
144. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: Benefits, risks, and challenges to implementation. AIDS 2010;24:1975-1982.
145. Mugo N, Celum C, Donnell D, Campbell J, Bukusi E. Pregnancy incidence and birth outcomes in a clinical trial of PrEP: Uganda and Kenya. Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, 2012. Abstract 1060.
146. The Antiretroviral Pregnancy Registry. Interim Report: 1 January 1989 through 31 January 2013. Published December 2013.
147. Sherin K, Klekamp BG, Beal J, Martin N. What is new in HIV infection? Am Fam Physician 2014;89:265-272.
148. United Nations. Department of Economic and Social Information and Policy Analysis. World Contraceptive Use 2011, 2012.
149. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Health Statistics Rep 2012;60: 1-25.
150. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: A systematic review of the epidemiological evidence. Lancet Infect Dis 2013;13: 797-808.
151. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: A systematic review of the epidemiologic evidence. AIDS 2013;27: 493-505.
152. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012;12:19-26.
153. Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: A systematic review. Contraception 2012;86:606-621.
154. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: Cost and access to insurance. Am J Prev Med 2013;44:S125-S128.
155. Person A, B Hicks C. Pre-exposure prophylaxis-one more tool for HIV prevention. Current HIV Res 2012;10: 117-122.
156. Vázquez E. Another blue pill for sex: Preventing HIV with Truvada PrEP-Already at a pharmacy near you. Positively Aware 2010;23:25-27.
157. Cohen J. Complexity surrounds HIV prevention advances. Science 2011;333:393.
158. Pals H, Waren W. Winners and losers in health insurance: Access and type of coverage for women in same-sex and opposite-sex partnerships. Women Health 2014;54: 94-114.
159. Lavelle B, Lorenz FO, Wickrama KA. What explains divorced womens poorer health? The mediating role of health insurance and access to health care in a rural Iowan sample. Rural Sociol 2012;77:601-625.
160. Fan ZJ, Anderson NJ, Foley M, Rauser E, Silverstein BA. The persistent gap in health-care coverage between lowand high-income workers in Washington State: BRFSS, 2003-2007. Public Health Rep 2011;126:690-699.
161. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: Experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013;17:2143-2155.